1
|
Manganelli M, Grossi I, Ferracin M, Guerriero P, Negrini M, Ghidini M, Senti C, Ratti M, Pizzo C, Passalacqua R, Molfino S, Baiocchi G, Portolani N, Marchina E, De Petro G, Salvi A. Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines 2021; 9:813. [PMID: 34356875 PMCID: PMC8301380 DOI: 10.3390/biomedicines9070813] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 01/10/2023] Open
Abstract
Human hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver and the third cause of cancer-related deaths. The multikinase inhibitor sorafenib is a systemic drug for unresectable HCC. The identification of molecular biomarkers for the early diagnosis of HCC and responsiveness to treatment are needed. In this work, we performed an exploratory study to investigate the longitudinal levels of cell-free long ncRNA GAS5 and microRNAs miR-126-3p and -23b-3p in a cohort of 7 patients during the period of treatment with sorafenib. We used qPCR to measure the amounts of GAS5 and miR-126-3p and droplet digital PCR (ddPCR) to measure the levels of miR-23b-3p. Patients treated with sorafenib displayed variable levels of GAS5, miR-126-3p and miR-23b-3p at different time-points of follow-up. miR-23b-3p was further measured by ddPCR in 37 healthy individuals and 25 untreated HCC patients. The amount of miR-23b-3p in the plasma of untreated HCC patients was significantly downregulated if compared to healthy individuals. The ROC curve analysis underlined its diagnostic relevance. In conclusion, our results highlight a potential clinical significance of circulating miR-23b-3p and an exploratory observation on the longitudinal plasmatic levels of GAS5, miR-126-3p and miR-23b-3p during sorafenib treatment.
Collapse
Affiliation(s)
- Michele Manganelli
- Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy; (M.M.); (I.G.); (E.M.)
| | - Ilaria Grossi
- Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy; (M.M.); (I.G.); (E.M.)
| | - Manuela Ferracin
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40126 Bologna, Italy;
| | - Paola Guerriero
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; (P.G.); (M.N.)
| | - Massimo Negrini
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; (P.G.); (M.N.)
| | - Michele Ghidini
- Department of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy; (M.G.); (C.S.); (M.R.); (C.P.); (R.P.)
| | - Chiara Senti
- Department of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy; (M.G.); (C.S.); (M.R.); (C.P.); (R.P.)
| | - Margherita Ratti
- Department of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy; (M.G.); (C.S.); (M.R.); (C.P.); (R.P.)
| | - Claudio Pizzo
- Department of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy; (M.G.); (C.S.); (M.R.); (C.P.); (R.P.)
| | - Rodolfo Passalacqua
- Department of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy; (M.G.); (C.S.); (M.R.); (C.P.); (R.P.)
| | - Sarah Molfino
- Department of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, Italy; (S.M.); (G.B.); (N.P.)
| | - Gianluca Baiocchi
- Department of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, Italy; (S.M.); (G.B.); (N.P.)
| | - Nazario Portolani
- Department of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, Italy; (S.M.); (G.B.); (N.P.)
| | - Eleonora Marchina
- Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy; (M.M.); (I.G.); (E.M.)
| | - Giuseppina De Petro
- Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy; (M.M.); (I.G.); (E.M.)
| | - Alessandro Salvi
- Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy; (M.M.); (I.G.); (E.M.)
| |
Collapse
|